Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Walgreens (WBA) reports sales growth and strategic initiatives progress

Walgreens (WBA) Q1 2025 earnings call highlighted sales growth, progress in pharmacy operations, and challenges in consumer retail business. The company is focusing on stabilizing its U.S. Retail Pharmacy business, improving operational efficiency, and driving long-term value creation. Opportunities exist in cost savings initiatives, strategic turnaround efforts, and sustained positive cash flow generation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance, Inc. (WBA) Q2 2024 Earnings Call Transcript

Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal second quarter benefited from higher branded drug inflation and strong execution in pharmacy services.

Walgreens Boots (WBA) Q2 Earnings Top Estimates, EPS View Down

Walgreens Boots Alliance (WBA) reported fiscal second-quarter revenue that beat estimates, though it posted a steep loss as it incurred billions of dollars in impairment charges.

Walgreens Reports Steep Loss Despite Revenue Beat on Nearly $6 Billion Impairment Charge

Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A)'s UK division, Boots, enjoyed a 3% rise in sales over the three months to February. This was as in-store sales climbed 4.5%, while digital sales jumped 16.8%, including on Boots' website and app.

Boots UK's sales climb on strong skincare demand

Although the revenue and EPS for Walgreens (WBA) give a sense of how its business performed in the quarter ended February 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Walgreens (WBA) Q2 Earnings: A Look at Key Metrics

Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A)'s fiscal second quarter results took a $5.8 billion hit from impairment charges on its investment in medical clinic operator VillageMD, sending its shares lower in early trade on Thursday.  For the quarter which ended February 29, 2024, Walgreens posted adjusted earnings per share (EPS) of $1.20, above estimates of $0.82.

Walgreens' quarterly results hit by $5.8B VillageMD impairment charge

Walgreens Boots Alliance's NASDAQ: WBA efforts are paying off, although they still have work to do. The company's leaning toward efficiency and efforts to reinvigorate growth, sustain growth and improve profitability will drive shareholder value over the long term.

Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up

Walgreens Boots Alliance (WBA) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $1.16 per share a year ago.

Walgreens Boots Alliance (WBA) Q2 Earnings and Revenues Beat Estimates

The pharmacy chain posted adjusted earnings of $1.20 a share, compared with analysts' expectations of 82 cents a share.

Walgreens Boots Alliance Posts Higher 2Q Sales, Narrows Earnings Guidance

Walgreens Boots Alliance Inc is trading up in premarket on Thursday after reporting upbeat financial results for its second quarter. Walgreens' guidance for the full year Investors are cheering also because the management issued encouraging guidance for the future.

Walgreens beats estimates in fiscal Q2

Shares of Walgreens Boots Alliance Inc. WBA, +2.49% gained 0.8% in premarket trading Thursday after the drugstore chain reported fiscal second-quarter adjusted profit and sales that rose well above expectations, but trimmed its full-year outlook. The company swung to a net loss for the quarter to Feb. 29 of $5.9 billion, or $6.85 a share, from net income of $703 million, or 81 cents a share, in the same period a year ago.

Walgreen's stock gains after big profit beat, while full-year outlook was lowered

Walgreen Boots Alliance narrowed its profit forecast for fiscal 2024 by on Thursday, citing economic challenges for its retail business, and also took a $5.8 billion impairment related to its VillageMD business.

Walgreens narrows full-year profit forecast and takes $5.8 billion impairment

Walgreens Boots Alliance lost nearly $6 billion in its second quarter as the company grapples with the loss in value of its investment in doctor-staffed clinic operator VillageMD.

Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours

Walgreens posted a steep net loss for the quarter as it recorded a hefty goodwill impairment charge related to its primary-care provider VillageMD.

Walgreens tops quarterly revenue estimates, but narrows profit outlook in 'challenging' economy

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the second quarter of fiscal 2024, which ended February 29, 2024. Chief Executive Officer Tim Wentworth said: "We're encouraged by our first quarter of U.S. Healthcare positive adjusted EBITDA and continued topline growth alongside another quarter of strong execution in pharmacy, as we look to re-energize and evolve its impact both at Walgreens and at large. As we continue to ope.

Walgreens Boots Alliance Reports Fiscal 2024 Second Quarter Results

The retail pharmacy chain reports results before the market open Thursday.

Walgreens Earnings Are Thursday. Investors Want to See Changes.

Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A), the retail pharmacist, will likely showcase how its strategy is evolving under newly appointed CEO Tim Wentworth at its second quarter update on Thursday. Wentworth took charge of the group back in October 2023 but analysts are keen to learn about how he plans to deploy capital from sales over the long term and whether a ‘back to basics' plan will be launched.

Walgreens Boots to reveal new CEO strategy in trading update

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Walgreens (WBA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended February 2024.

Countdown to Walgreens (WBA) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Carnival

GameStop

The stock market will be closed on Good Friday. Plus, core PCE price index inflation data and earnings from GameStop, Carnival, and Walgreens Boots Alliance.

Walgreens, Carnival, GameStop and More to Watch This Week

Pfizer

After falling significantly, a pair of healthcare stocks offer above-average yields. New cancer drugs could lead to years of growth for Pfizer, but the pharma stock has been beaten down.

2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?

In the closing of the recent trading day, Walgreens Boots Alliance (WBA) stood at $20.58, denoting a -1.06% change from the preceding trading day.

Walgreens Boots Alliance (WBA) Declines More Than Market: Some Information for Investors

CNBC's Jim Cramer on Friday guided investors through next week's most important happenings on Wall Street.

Jim Cramer's week ahead: New consumer data and earnings from Walgreens

In the latest trading session, Walgreens Boots Alliance (WBA) closed at $20.80, marking a -1.38% move from the previous day.

Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: Here's Why

Walgreens Boots Alliance has opportunities to acquire Rite Aid stores and expand its geographic presence. Cost savings, deleveraging, lower interest rates and the opportunity to acquire some Rite Aid stores are strong catalysts. It is one of the best value plays on the market because some valuation metrics are at a 10-year low.

Walgreens: One Of The Best Value Picks At The Moment

Walgreens Boots Alliance, Inc. faces challenges in its retail pharmacy business due to lower demand for COVID-19 testing and tight prescription drug payouts. The company is transitioning into a healthcare powerhouse, investing in primary care practices and offering in-home health services. Despite declining earnings and cash flow, there is potential for a rebound as Walgreens stock is undervalued and sales are growing in the healthcare division.

News for Walgreens Stock (WBA)